DR5 expression is most common in bone sarcomas (e.g., Ewing’s sarcoma, osteosarcoma, and chondrosarcoma) as well as hematological tumors such as myeloma (Surget et al., 2012; Picarda et al., 2010; Chen W. et al., 2021; Newton, 2023). This evidence concerns the gene TNFRSF10B and plasma cell myeloma.